↓ Skip to main content

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

Overview of attention for article published in Oncogene, December 2000
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

patent
13 patents

Citations

dimensions_citation
463 Dimensions

Readers on

mendeley
173 Mendeley
citeulike
1 CiteULike
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Published in
Oncogene, December 2000
DOI 10.1038/sj.onc.1204097
Pubmed ID
Authors

Stanley Zucker, Jian Cao, Wen-Tien Chen

Abstract

Experimental studies performed prior to 1990 led to the widely held belief that matrix metalloproteinases (MMPs) produced by cancer cells are of critical importance in tumor invasion and metastasis. Based on this evidence, the pharmaceutical industry produced several well tolerated, orally active MMP inhibitors (MMPIs) which demonstrated efficacy in mouse cancer models. Phase III clinical trials initiated in 1997-98 using marimastat, prinomastat (AG3340), and BAY 12-9566 alone or in combination with standard chemotherapy in patients with advanced cancers (lung, prostate, pancreas, brain, GI tract) have recently been reported; no clinical efficacy was demonstrated. Bayer and Agouron have discontinued their ongoing Phase III drug trials of MMPIs in advanced cancer. In retrospect, the failure of MMPIs to alter disease progression in metastatic cancer might have been anticipated since MMPs appear to be important in early aspects of cancer progression (local invasion and micrometastasis) and may no longer be required once metastases have been established. Our understanding of MMP pathophysiology in cancer has expanded considerably in the past 10 years. Current views indicate that: (1) most MMPs in tumors are made by stromal cells, not carcinoma cells; (2) cancer cells induce stromal cells to synthesize MMPs using extracellular matrix metalloproteinase inducer (EMMPRIN) and cytokine stimulatory mechanisms; and (3) MMPs promote cell migration and the release of growth factors sequestered in the extracellular matrix. MMPs have a dual function in tumor angiogenesis: MMP-2 and MT1-MMP are required in breaking down basement membrane barriers in the early stage of angiogenesis, while other MMPs are involved in the generation of an angiogenic inhibitor, angiostatin. In spite of considerable recent progress in identifying multiple roles of MMPs in disease, our understanding of MMP function in cancer is far from complete (see Table 1). Based on accumulated data, it is recommended that future MMPI trials focus on: (1) patients with early stage cancer; (2) the use of MMPIs along with chemotherapy; (3) the measurement of MMPs in tumor tissue and blood as a means of identifying patients who are more likely to respond to MMPI therapy; and (4) identification of biomarkers that reflect activation or inhibition of MMPs in vivo.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 2%
Germany 2 1%
United States 2 1%
Italy 1 <1%
Czechia 1 <1%
Portugal 1 <1%
Unknown 163 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 38 22%
Researcher 25 14%
Student > Bachelor 23 13%
Student > Master 17 10%
Professor 12 7%
Other 37 21%
Unknown 21 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 43 25%
Medicine and Dentistry 30 17%
Biochemistry, Genetics and Molecular Biology 27 16%
Chemistry 10 6%
Pharmacology, Toxicology and Pharmaceutical Science 7 4%
Other 27 16%
Unknown 29 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2023.
All research outputs
#3,282,218
of 22,846,662 outputs
Outputs from Oncogene
#1,338
of 10,650 outputs
Outputs of similar age
#6,549
of 114,487 outputs
Outputs of similar age from Oncogene
#8
of 95 outputs
Altmetric has tracked 22,846,662 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,650 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 114,487 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.